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The ultimate test of HIV remission is maintenance of undetectable
plasma viraemia off antiretroviral therapy. Several studies, both
past and recent have explored how common this phenomenon
is and what factors predict successful viral control where present.
There is no unifying definition of post-treatment control (PTC),
in terms of length of time plasma viral load (VL) remains below
a certain threshold and comparison between studies demonstrates
a variable definition of the phenotype. Table 1 summarises
studies presented at the meeting where individuals were enrolled
into a carefully monitored analytical treatment interruption
(ATI) strategy. Overall, despite many years of successful viral
suppression and CD4 recovery, PTC was uncommon. Where
virus rebounded, this occurred generally within the first 2–8
weeks after ATI
The ULTRASTOP study selected 10 participants who initiated
antiretroviral therapy (ART) in early chronic HIV infection and
exhibited tight viral control with low HIV RNA and DNA, and
high CD4 and CD4/CD8 ratio. Half of the cohort had protective
HLA alleles associated with elite controllers and PTC status. Despite
these favourable qualities, nine of 10 participants had a rapid
viral load rebound post-ATI. One participant has controlled viraemia
below 400 copies/mL for over 1 year. He possesses HLA-B2703
that could have contributed to the prolonged viraemic control,
although others with such HLA profile in this cohort did not
[1,2].
The pooled ACTG analyses examined the relationship between time
to VL rebound and VL set point post-ATI. They observed that
longer time to VL rebound and earlier ART initiation was associated
with lower VL set point. VL set point in these studies was defined
as the mean plasma viral load measured in HIV RNA copies/mL
taken 12‒16 weeks after TI. VL set points were similar with
non-nucleoside analogue- and protease inhibitor-based regimens.
In chronically treated individuals, pre-ART VL was positively
associated with levels of VL set point. Interestingly, set point VL
was two-fold lower than pre-ART VL, which cautions against using
lower VL levels at set point compared to pre-ART as an indicator
for efficacy of interventions in studies without a control arm [3,4].
The SPARTAC investigators presented data from the African
SPARTAC cohort that enrolled 82 females from sub-Saharan Africa
with subtype C primary HIV infection. Participants were randomly
allocated to no ART (n=38) vs 48 weeks of ART (n=44). Of those
treated for 48 weeks, 22 with VL <400 copies/mL underwent ATI
and five achieved PTC status at week 48 (PTC rate of 22%) [5].
This is higher than that observed in the UK SPARTAC cohort (PTC
rate of 5%) [6]. However, the predictors for time to VL rebound
in the UK cohort were not replicated here (total HIV DNA and
markers of immune exhaustion) [7,8]. These findings illustrate the
potential contribution of host (gender, ethnicity) and viral subtype
on HIV remission, and highlight the limitation of extrapolating
findings across populations.
Interventions in addition to ART amongst chronically infected
individuals with years of sustained viral suppression were also
presented. Two studies presented findings following infusion of
the broadly neutralising antibody (bNAb) VCR01 [9,10]. VRC01
targets the CD4 binding site of HIV Env and neutralises ~90%
of HIV isolates with high potency (mean IC50 0.33 μg/mL, mean
IC80 1 μg/mL). In both studies, infusion of the antibody was
safe and well tolerated, and achieved plasma levels of antibody
at least 50-fold above the IC80. In the ACTG5340 study, 13
chronically HIV-infected males with long-term viral suppression
received VRC01 1 week prior to ATI and every 3 weeks post-ATI.
All experienced viral rebound >200 copies/mL, and in the
majority, it occurred rapidly within the first 5 weeks. There was a
trend towards delayed initial rebound with 38% of participants
in this study maintaining viral suppression at week 4 compared
to 13% in the historical ACTG cohort without any intervention
[11], but this did not persist after week 4. In the NIAID study,
10 participants who had been VL suppressed for about a decade
interrupted ART after receiving VRC01 3 days prior and every
2–4 weeks subsequently. All except one rebounded at a median
time of 39 days. Pre-existing and rapid emergence of VRC01
was likely to contribute to the failure of VRC01 to suppress
viraemia. These findings suggest that in chronic HIV infection,
combination bNAbs will probably be needed to control viraemia
post-ATI.
In the combination intervention pilot study amongst chronically
infected virally suppressed individuals in the Reduc study,
participants received Vacc-4x vaccination [12] with RhGM-CSF
adjuvant, followed by a latency-reversing agent (LRA), romidepsin
[13]. The regimen was safe and well tolerated. Eight of 17
participants showed detectable viraemia with romidepsin
infusions. Data on 6/17 individuals enrolled showed a modest
reduction in total HIV DNA of 40% and in viral outgrowth
assay of 36% after completion of the intervention. However,
subsequent ATI led to all participants experiencing rapid viral
rebound to >50 copies/mL HIV RNA by day 14. The vaccine did
not appear to generate HIV-specific CD8 immune responses
[14].
An interesting study in rhesus macaques showed that toll-like
receptor (TLR)-7 agonist given in addition to ART could lead to
simian immunodeficiency virus (SIV) remission. In 11 rhesus
monkeys infected with SIVmac251 and initiated on ART at day
65 post-infection, different doses of TLR7 agonist (n=9) vs
placebo (n=2) were given starting at day 467 post-infection.
SIV DNA levels were reduced in memory CD4+ T cells in
TLR7-agonist treated monkeys on ART. In seven of nine
TLR7-agonist treated animals, reductions of inducible RNA were
observed. Of interest, two animals had undetectable inducible
virus from blood and lymph node cells before stopping ART, and
they did not experience viral rebound after more than 3–4
months off ART [15].
These studies constitute promising work that highlights the
difficulty in achieving the goal of HIV remission and cure.
Earlier initiation of ART can prolong time to VL rebound, but by
itself, will not be enough to ensure that the majority of people
can achieve remission. Combination therapies will be needed
and may include potent latency-reversing agents, two or three
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bNAbs with different targets and/or therapeutic vaccines that
generate strong HIV-specific immune responses.
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Table 1. Analytical treatment interruption studies with and without immunological interventions
Study Design Primary outcomes Participants Findings
Without immune interventions
ULTRASTOP
[2]
ATI in early treated
chronically infected
persons with low HIV DNA
and high CD4
Frequency of PTC
(VL <400 copies/
mL post-ATI)
10 participants (7 male) with
median CD4 1118 cells/mm3,
CD4/CD8 ratio 0.9 and HIV
DNA <66 copies/106 PBMCs
with median time on ART of 5
years
Five were either HLA-B27 or
HLA-B57 positive
1/10 had VL <400 copies/mL at week 48 post-ATI (PTC
rate 10%, 95% CI 0.3–44.5). This participant had CCR5
wild-type virus and was positive for HLA-B2703, HLA-
B4001
9/10 had VL rebound at week 2 (n=2), week 4 (n=6) and
week 12 (n=1)
Median (range) time to VL rebound was 4 (2–12) weeks
ACTG [4] Pooled analysis of six
ACTG ATI studies
Association
between time to
VL rebound ≥200
copies/mL and VL
set point (mean VL
between weeks
12–16)
235 participants (91% male)
on suppressive ART initiated
in recent (34%) and chronic
HIV (66%) infection
Median time on ART was 5.1
years
14 participants with VL rebound >12 weeks post-ATI had
lower VL set point than the 180 who rebounded at ≤12
weeks post-ATI (median 1.9 vs 4.1 log10 copies/mL,
P<0.001)
Participants treated in recent HIV infection had lower VL
set point than those treated later (median 3.5 vs 4.2
log10 copies/ml, P<0.001)
In chronically treated individuals, pre-ART VL was
associated with VL set point level but not time to VL
rebound. VL set point was two-fold lower than pre-ART
VL
SPARTAC
[5]
Randomised trial of no
ART vs 48 weeks during
primary HIV infection
followed by ATI
Frequency of PTC
(VL <400 copies/
mL post-ATI)
22 female participants from
sub-Saharan Africa with
subtype C HIV
5 of 22 African participants had VL <400 copies/mL
post-ATI (PTC rate 22%) over a median of 188 weeks
(range 147–203)
No predictive biomarkers of time to VL rebound were
observed
With immune interventions
ACTG5340
[9]
Single-arm study of
VRC01 bNAb during ATI in
chronically treated
individuals. VRC01 40 mg/
kg/dose given at −1 week,
and q 3 weeks post-ATI
Safety, tolerability,
plasma VRC01
level
Time to VL
rebound >200
copies/mL
13 male participants on
suppressive ART initiated in
chronic HIV
Median of 4.7 years on ART
VRC01 was safe and well tolerated
Plasma VRC01 levels were >50 μg/mL post-ATI (mean
IC80 of VRC01 is 1 μg/ml)
All participants had VL rebound (11 by week 5, one by
week 8 and one by week 11)
38% in this study vs 13% in a historic cohort remained
with VL suppression at week 4, P=0.04
Rebound virus displayed clonal selection and pre-existing
resistance
NIAID [10] Single arm study of VRC01
bNAb administered at day
−3 and weeks 2, 4 and q 4
weeks post-ATI
Safety, tolerability,
plasma VRC01
level
Time to VL
rebound >40
copies/mL
10 participants on suppressive
ART initiated in chronic HIV
Mean of 10.6 years on ART.
VRC01 was safe and well tolerated. All had high plasma
concentrations of VRC01
9/10 experienced viral rebound >40 copies/mL between
11–86 days (median 39 days)
Pre-existing and rapid emergence of VRC01-resistant
viruses likely contributed to viraemia
Reduc [14] Single arm study of Vacc-
4x (four modified peptides
to p24) 1.2 mg ID with
RhGM-CSF adjuvant
0.06 mg ID given at days
0, 7, 14, 21, 77 and 84
plus romidepsin 5 mg/m2
IV at days 105, 112 and
119, followed by ATI on
day 182
Safety, tolerability
Time to VL >50
copies/mL
20 participants (17 males) on
suppressive ART initiated in
chronic HIV infection
Median time on ART was 6.3
years
Median total HIV DNA at
baseline was 1080 copies/106
CD4
The combination was safe and well tolerated
All participants had VL rebound >50 copies/mL at a
median time of 14 days post-ATI
8/17 (47%) had detectable plasma viraemia during
romidepsin infusions
Prior to ATI, data on 6/17 participants showed a mean
reduction of total HIV DNA of 39.7% (95% CI: −11.5–
−58.9) and for viral outgrowth assay (IUPM), it reduced
by 38% (95% CI: −67– −8)
HIV-specific CD8 immune responses were similar before
and after the intervention
ATI: analytical treatment interruption; PTC: post-treatment controller; PBMC: peripheral blood mononuclear cells; VL: viral load; bNAb: broadly neutralising
antibody
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Reservoirs, relapse and remission
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Investigating the mechanisms that control HIV transcription
and latency in vivo
The mechanisms that maintain HIV latency in vivo, and the role
of transcriptional interference in limiting HIV transcription are yet
unclear. Yukl et al.‘s hypothesis was to investigate whether levels
of different HIV RNA transcripts could be used to infer the sites
of transcriptional blockade [1]. To answer this hypothesis they used
CD4+T cells from nine ART-suppressed individuals, which were
subsequently activated for 2 days with anti-CD3/CD28 beads or
not activated. The purified RNA from the samples was than assayed
with ddPCR for specific and different HIV transcripts indicative
of: (1) transcriptional interference (U3-U5; ‘read-through’); (2)
initiation (TAR); (3) elongation (R-U5-tRNA; ‘long’); (4) completion
(3′LTR-polyA; ‘polyA’); and (5) multiple splicing (tat-rev). The group
found a relative abundance of HIV transcripts in unstimulated
CD4+T cells, indicating blocks to proximal elongation, completion
and splicing. Hence, in unstimulated CD4+T cells the transcriptional
interference was found to play a modest role in limiting HIV
transcription, while blocks in elongation, completion and splicing
dominated. In contrast, the CD4 T cell activation was found to
increase all transcripts. More specifically, activation was found to
selectively increased distal and spliced transcripts but had less
effect on read-through or total transcripts, suggesting that the
main reversible blocks to HIV expression are not interference or
lack of initiation, but rather inhibition of elongation/
polyadenylation and splicing.
Human galectin-9 is a potent mediator of HIV transcription
and reactivation
HIV transcription, more specifically host determinants that govern
HIV transcription and latency are one of the several research
focuses in HIV cure studies. In this sense and based on previous
findings, Abdel-Mohsen et al. [2] presented new data on glycan-
binding protein galectin-9 (Gal-9) and its mediation in HIV
transcription and reactivation. The same group previously showed
that human Gal-9 regulates p21 (the host factor) and in turn p21
regulates HIV transcription during antiretroviral therapy (ART).
Therefore, for this research they hypothesised that Gal-9 modulates
HIV transcription. To test this hypothesis they used plasma from
72 HIV-infected ART-suppressed individuals. In addition, by using
the J-Lat 5A8 HIV latency model and primary CD4+ T cells isolates
from 13 HIV-infected ART-suppressed individuals, the group
evaluated the ability of a recombinant, stable form of Gal-9
(rGal-9) to reactivate latent HIV. In addition, the group used the
enzymatic and chemical deglycosylation to explore the requirement
of glycans in viral reactivation by rGal-9. In summary, their findings
indicated that the cell surface N-linked oligosaccharides and
O-linked hexasaccharides were essential for rGal-9-induced HIV
reactivation, mediated by key transcription initiation, promoter
proximal-pausing, and chromatin remodelling factors. More
importantly, rGal-9 was found to reactivate latent HIV more
potently than anti-CD3/CD28 stimuli and to induce expression
of the host antiviral deaminase APOBEC3G in vitro and ex vivo.
Hence, rGal-9-induced virus is suggested to be replication
incompetent as a result of APOBEC3G induction in the producer
cell, which than will ensure that the reservoir will not be replenished
when latency is reversed therapeutically, even in the setting of
suboptimal ART suppression.
1PD-1+ and Tfh cells represent the major source of HIV-1
replication-competent virus
In the past few years, research has shown that T follicular helper
(Tfh) cells are the major CD4 T cell compartments for HIV infection
and replication, specifically in viraemic HIV-1-infected individuals.
Banga et al. [3] asked the question of what is the role of Tfh in
long-term treated aviraemic HIV-1 patients. Hence, they
investigated the distribution of CD4 T cells containing replication-
competent virus within CXCR5-PD-1-, CXCR5+PD-1- and PD-1+
memory CD4 T cell populations isolated from blood and lymph
nodes (LN) of 11 long-term treated (1.5–14 years) aviraemic
subjects. The results revealed that the levels of HIV-1 RNA
produced in LN PD-1+ CD4 T cells were higher (810–1225 fold
higher) as compared to blood and were found to be inversely
correlated with the duration of treatment. Interestingly, they found
that HIV-1 produced by LN PD-1+ CD4 T cells was also infectious
when tested in vitro with CD4 T cells of HIV-negative subjects.
Hence, these findings showed that LN PD-1+ CD4 T cells were
enriched with replication-competent virus and that these cells
represent the major source of replication-competent, infectious
virus in long-term treated aviraemic HIV-1-infected individuals.
Rapid accumulation of defective proviruses complicates
HIV-1 reservoir measurements
It is well known that defective proviruses predominate in resting
CD4+ T cells from patients treated with combined antiretroviral
therapy. Brunner et al. [4] investigated if the fraction of defective
proviruses is constant or increases over the course of the infection.
This could be supported by the idea that cells with genetically
intact proviruses are eliminated during suppressive therapy. To
answer this question an in vitro infection of CD4+ T cells was
performed to determine the fraction of defective proviruses after
a single round of infection. In addition proviruses from patients
treated in either acute or chronic infection and untreated viraemic
patients were characterised. Proviruses were analysed by an
unbiased, limiting dilution, full genome PCR and direct sequencing
of PCR products. The number of intact proviruses was quantified
as a percentage for each patient and compared to total HIV-1
DNA ddPCR values and quantitative viral outgrowth assay (QVOA)
IUPMs. Defective proviruses made up 40% of proviruses in the
one round in vitro replication set up. Moreover, less than 5% of
proviruses were intact in both patient groups; the remaining
proviruses contained major defects. In a comparative study, the
QVOA underestimates the latent reservoir by a median of 64-fold
in chronically treated patients and 20-fold in acutely treated patients
while total DNA PCR measurements vastly overestimated the
reservoir in both patient groups. An additional finding was that
during acute infection, the fraction of defective proviruses is likely
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to increase very rapidly, quickly making up over 95% of proviruses
in HIV-1 patients.
Clones of SIV-infected cells are present in spleen and lymph
nodes in rhesus macaques
Because there are limits on the samples that can be obtained from
patients, Ferris et al. [5] developed a model using SIV-infected
rhesus macaques. An integration site library from rhesus macaque
PBMCs infected in culture with SIV was generated. In addition
six additional libraries were generated from two rhesus macaques
that were infected with SIV for 4 weeks and then treated for
approximately 1 year with a cART regiment. One important finding
was that the distribution of the SIV integration sites in the large
integration site library (~50,000 independent sites) prepared from
the rhesus macaque PBMC infected in vitro was quite similar to
the distribution of HIV integration sites in human PBMCs. The
group identified the presence of expanded clones in two SIV
macaques that were treated after 4 weeks of infection indicating
that cells that are infected early can give rise to expanded clones.
Cells from two clones were present in both lymph node and spleen,
showing that the distribution was not tissue restricted. In this first
experiment, there was no evidence for the selection of cells that
have integration sites in either BACH2 or MKL2.
ART reduces cellular HIV RNA but not the fraction of
proviruses transcribing RNA
Hong et al. [6] performed an interesting study investigating both
the fraction of infected cells that express HIV RNA and the levels
of HIV RNA in single cells from untreated, viraemic individuals
and from those on suppressive ART. PBMCs from five viraemic
(median VL=5727 copies/mL) and five ART-suppressed (VL<20
copies/mL) individuals were analysed for expression of unspliced
viral RNA in single cells using two methods: cell-associated RNA
(CAR) and DNA single-genome sequencing (CARD-SGS), and
fractional proviral expression (fPVE). Importantly, the proportion
of the proviruses that expressed unspliced CAR was not different
between viraemic and ART-suppressed individuals (median 7% vs
6%, respectively). By contrast, the fraction of cells that were ‘high
CAR producers’ (>20 CAR copies/cell) was greater in viraemic than
suppressed individuals. The differences in HIV RNA expression
levels in single cells between ART-suppressed and viraemic
individuals suggest that cells producing high levels of HIV RNA
are associated with active virus replication and are eliminated by
viral CPE or CTL responses, whereas the more frequent cells
expressing low levels of HIV RNA can persist and expand despite
ART.
Restricted HIV-1 diversity and clonal expansion following
cytoreductive chemotherapy
Cytoreductive chemotherapy for malignancies does not lead to
consistent changes in HIV-1 DNA or RNA. However, observed
reductions in CD4 T cells during chemotherapy suggest that total
body reservoirs decrease. Henrich et al. [7] evaluated whether
constriction and subsequent oligoclonal expansion of HIV diversity
may be a better measure of the reservoir response to novel HIV
eradication strategies. Longitudinal, single-genome analysis of HIV
envelope sequences was performed in a cohort of 10 infected
individuals on suppressive ART receiving chemotherapy. Although
CD4 T cell counts transiently decreased by up to 75% during
chemotherapy, CD4 T cell HIV DNA did not change and RNA
increased following completion of therapy. Clonal expansion of
HIV-1 envelope sequences following chemotherapy was observed
in three of six patients for whom data was obtained; sequence
clustering was only seen following completion of chemotherapy.
Importantly, CD4 T cells that responded to EBV/CMV lysates had
higher HIV-1 DNA levels compared to those that responded to
αCD3/αCD28 stimulation or did not express IL2/IFN-γ. Hence,
these data also suggest that response to non-HIV antigens can
lead to oligoconal expansion of the DNA reservoir.
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The microbiome affects everything
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Microbes, in the setting of HIV infection, are likely to be playing
a large role in contributing to HIV-1 pathogenesis, morbidities and
mortality. Two major disruptions to microbial systems in HIV-1
infection include microbial translocation (MTL) and microbiome
dysbiosis [1]. MTL occurs when bacteria (or bacterial products)
translocate from the lumen of the intestine across the epithelial
barrier into systemic circulation, where they contribute to
inflammation and pathogenesis. In rhesus macaques, MTL begins
during the late acute phase of SIV infection and increases during
chronic infection and is associated with structural damage of the
gastrointestinal (GI) tract. Moreover, immune activation is
temporally and causally related to MTL and the relative inability
of intestinal macrophages to bind/phagocytose translocated
microbial products [2]. In addition, microbial populations in the
GI tract are also altered after HIV infection, resulting in microbiome
dysbiosis, which further exacerbates MTL, epithelial barrier
disruption, inflammation and mucosal immune functioning. A
dysbiotic mucosal-adherent community enriched in Proteobacteria,
among them many pathogens, and depleted of Bacteroidetes and
Firmicutes is associated with disruption of mucosal barriers, immune
activation and chronic inflammation in HIV-1 infected patients
[3,4].
During chronic HIV-1 infection, microbial products migrate into
the blood from the GI tract concomitant with systemic immune
activation. Ericsen et al. [5] reported that within the first week
of SIV infection (hyperacute infection) plasma levels of bacterial
DNA increased transiently as much as 1300-fold and plasma genera
detected in the stool up to 40% over baseline. In addition, he
also observed an increase of circulating IFABP, a marker of
enterocyte loss, suggesting that there is permeability within the
GI lining. Plasma levels of soluble CD14 (sCD14) correlated with
set-point levels of virus replication. In addition, this hyperacute
MTL was accompanied by peripheral inflammation and an increase
in peripheral CD4+CCR5+ T cells, suggesting that this might promote
early virus replication.
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During the themed discussion lead by Nichole Klatt, Luévano
et al. detailed [6] the impact of HIV-associated changes in the
gut microbiome on disease progression. Based on faecal material
from HIV-uninfected subjects, his data demonstrated a high
intra-subject bacterial community variability (richness) and a unique
population primarily composed of Firmicutes. During HIV-1
infection significant changes in the gut microbiome were observed,
showing a decrease in richness and change in composition with
a decrease of Firmicutes and an increase of Bacteroidetes. With
antiretroviral treatment those changes were less significant, but
did not return to those observed in HIV-uninfected individuals.
These alterations suggest that the enteric microbiome is
significantly altered by HIV-1 infection and may directly contribute
to disease progression.
From there the discussion moved on to the effect of the
microbiome on HIV-1 induced immunity with Dillon et al. [7]
showing how an altered gut microbiome enhances mucosal CD4
T cell infection and depletion ex vivo. Employing a model using
lamina propria mononuclear cells (LPMC) isolated from human
jejunum she showed that the majority of HIV-altered mucosal
bacteria (HAMB) increased HIV-1 infection and depletion of LP
CD4 T cells. However, Gram-negative HAMB enhanced CD4 T cell
infection to a greater degree than Gram-positive HAMB. In this
context, lipopolysaccharide, a Gram-negative bacteria cell-wall
component, upregulated CCR5 expression on LP CD4 T cells
whereas Gram-positive cell wall lipoteichoic acid did not. Thus
enhanced infection appears to be primarily mediated indirectly
through increased expression of CCR5 on LP CD4 T cells without
concomitant large-scale T cell activation. This represents a novel
mechanism potentially linking intestinal dysbiosis to HIV-1 mucosal
pathogenesis and is in concordance with the data shown by Ericsen
et al. [5].
The themed discussion closed with a presentation on how the gut
microbiome can be modulated during HIV-1 infection to improve
disease outcome. Somsouk et al. [8] presented data on a faecal
microbial transplantation (FMT) study aimed at reversing HIV-1
induced dysbiosis. In this open-label FMT study of six HIV-positive,
ART-suppressed participants the donor microbiome, enriched with
Bacteroidetes and Faecalibacterium was delivered by colonoscopy.
After FMT, the recipient microbiome significantly shifted towards
the donor microbiome indicated by UniFrac distance, showing the
similarity between microbiobial communities. The degree of
microbial engraftment was modest with a single delivery of FMT,
and the effect on inflammation remains to be determined.
Taken together, even though it is clear that HIV-1 infection
damages the GI mucosa leading to MTL, which is accompanied
by intestinal dysbiosis, it remains under examination if dysbiosis
is the cause or rather the symptom. This makes it imperative to
better understand the complex relationships between the gut
microbiome and mucosal dysfunction to develop new therapeutic
strategies in the management of chronic HIV and, potentially, other
chronic inflammatory conditions.
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Interventional studies for complications of HIV
disease: from bench toward the clinic
Jaime H Vera
Lawson Unit, Brighton and Sussex University NHSTrust and Brighton and Sussex
Medical School, UK
The introduction of combination antiretroviral therapy (cART) has
transformed HIV disease into a manageable long-term chronic
condition. Despite this, there is convincing evidence that compared
to the general population people living with HIV (PLWH) have
an increased rate of comorbidities such as cognitive impairment,
cardiovascular, liver and bone disease. The reasons for this are
multifactorial including immune activation, antiretroviral therapy,
specific lifestyle and the HIV virus itself [1]. There is an urgent
need for novel treatment strategies to tackle non-AIDS
comorbidities of PLWH on effective cART as well as those
commencing cART. A major theme of the scientific presentations
at the 2016 CROI was the investigation of novel interventions for
the management of complications in HIV disease.
HIV-associated cognitive disorders (HAND) are frequently reported
in PLWH on effective cART, and have been strongly associated
with persistent central nervous system inflammation [2]. Although
adjunctive therapies are likely to play a role in the management
of HAND, medication treatment strategies for HAND have been
disappointing. Sacktor and colleagues [3] presented findings from
a trial of paroxetine and fluconazole therapy for HAND. After
screening over 2000 approved compounds for neuroprotection,
they selected fluconazole and paroxetine because of their potent
immunoprotective effects in in vitro and SIV models of
mitochondrial stress and neuronal damage. Forty-five HIV-positive
individuals with evidence of cognitive impairment were enrolled
in a 24-week randomised double-blind placebo-controlled trial
where participants were assigned to one of four groups: (1)
paroxetine 20 mg daily; (2) fluconazole 100 mg twice a day; (3)
paroxetine plus fluconazole; and (4) placebo. The study showed
benefit in cognitive performance in HIV-positive individuals in the
paroxetine arms (alone or in combination with fluconazole)
compared to the non-paroxetine arms, after adjusting for
depression. There was no benefit in cognitive performance in
HIV-positive individuals on the fluconazole arms; however,
fluconazole was associated with a reduction of CSF ceramide, a
marker of oxidative stress. Interestingly, cognitive improvement
in the paroxetine arms was not associated with reductions in CSF
lipid markers of oxidative stress. The investigators concluded that
paroxetine might be associated with cognitive improvement in
patients with HAND. Although a larger study is needed to
corroborate the findings, these results are encouraging as they
show a beneficial effect of adjunctive therapy for HAND in a
randomised controlled trial. In another translational medicine study,
Ofotokun and colleagues [4] demonstrated in a randomised
double-blind placebo-controlled trial that a single infusion of
zolendronic acid at the time of ART initiation prevented ART-
induced bone resorption and bone mineral density (BMD) loss in
HIV-positive individuals initiating cART (atazanavir/ritonavir +
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tenofovir/entricitabine) after 48 weeks. It is well established that
HIV infection is an independent risk factor for bone mineral loss,
and that initiation of cART can induce additional loss in bone
mineral density (BMD)[5]. BMD loss in the context of HIV occurs
early, and irrespective of the type of cART, suggesting a
mechanistic role of immune reconstitution. Using a mouse model
of HIV immune reconstitution the authors previously demonstrated
that zolendronic acid significantly inhibited immune reconstitution,
preventing bone resorption and mineral loss [6]. They have now
moved a step forward and demonstrated the potential of using
zolendronic acid prophylactically to prevent BMD loss associated
with both HIV and initiation of cART.
In summary, findings from these translational clinical studies, if
replicated in larger clinical trials, are a step forward in the search
for management strategies for non-AIDS comorbidities affecting
PLWH.
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LATTE 2 study
Ellen Dwyer
St George‘s University Hospitals NHS Foundation Trust, London, UK
Over the past 20 years the contents of the HIV physician‘s
treatment toolbox have improved dramatically. Patients now have
access to an array of antiretroviral medications with low side-effect
profiles that require only once-daily dosing, often in single-tablet
combinations. Despite significant treatment advances, the impact
of antiretroviral therapy is limited by incomplete adherence, a major
cause of treatment failure, and the emergence of pharmacological
resistance.
In other fields of medicine, including psychiatry and reproductive
health, improvements in adherence have emerged through the use
of long-acting injectables [1]. Similar agents may offer a more
convenient method of antiretroviral administration, potentially
improving adherence and patient satisfaction.
David Margolis’ presentation of the 32-week results from the
LATTE-2 (Long-Acting Antiretroviral Treatment Enabling) trial [2]
described a major advance in the development of injectable
antiretroviral agents. It analysed a combination injectable
containing the integrase inhibitor cabotegravir (previously GSK
744) and the non-nucleoside reverse transcriptase inhibitor
rilpivirine. The main objectives were to investigate the safety and
efficacy of this regimen in treatment maintenance, and establish
an appropriate dosing schedule for progression into Phase III
studies. The efficacy of the oral cabotegravir/rilpivirine combination
had been studied in LATTE-1 [3], and was shown to be non-
inferior to efavirenz and two nucleoside reverse transcriptase
inhibitors in a 72-week maintenance phase.
The LATTE-2 Phase IIb multicentre open-label study recruited 309
individuals, all of whom received oral therapy during the induction
phase of the trial (oral cabotegravir and Kivexa for 20 weeks, with
oral rilpivirine being added in the last 4 weeks) in order to assess
for potential hypersensitivity and intolerability. Of these, 286
individuals became virologically suppressed, and were then randomly
allocated to one of three arms. The first arm (n=56) continued oral
treatment (cabotegravir and Kivexa), the second received the
combination intramuscular injectable (rilpivirine and cabotegravir)
every 4 weeks (n=115), and the third group received the injectable
every 8 weeks (n=115). Viral suppression levels remained high in
all arms (91% in oral arm, 94% in 4-weekly dosing and 95% in
8-weekly dosing). Serious adverse events were low overall; however,
high levels of mild–moderate injection site reactions were reported
(93% described injection site pain). Despite this, patient satisfaction
in all arms of the trial was high, and was actually greater (90%) in
the injectable compared to the oral daily-dosing arm (70%).
LATTE-2 provides good evidence for both the efficacy and the
acceptability to patients of injectable agents. If the cabotegravir/
rilpivirine and other injectable combinations are further developed,
they are likely to have a major impact on patient lifestyle and
satisfaction, including allowing patients greater freedom to travel
without medications. These long-acting medications may also
provide a key tool to help us effectively treat populations including
drug users and adolescents, in whom adherence issues remain a
major barrier to the provision of effective treatment.
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FDG PET/CT imaging of lymph nodes as a
measure of the HIV reservoir in humans
Jasmini Alagaratnam
Clinical Trials Unit, St Mary‘s Hospital, Imperial College London, UK
Lymphoid structures have been identified as a major HIV reservoir,
with evidence of ongoing viral replication despite suppressive
antiretroviral therapy (ART) [1]. Hsue et al. assessed the association
between axillary lymph node (LN) inflammation (using 18F-
fluorodeoxyglucose (FDG) PET/CT imaging) and size ofHIV reservoir
[2]. Tissue with high glucose metabolism (e.g. in inflammation)
show a preferential uptake of FDG (an analogue of glucose) [3,4].
This prospective observational study recruited 73 individuals; 44
HIV-infected individuals of whom 34 were suppressed on ART, seven
elite controllers, three not on ART and 29 matched HIV-uninfected
controls. FDG uptake (as a proxy for inflammation) in the axillary
LN was assessed as a mean standardised uptake value (SUV). A
target to background ratio (TBR) for LN was generated by dividing
LN SUV by blood background SUV. Frequency of cells harbouring
integrated HIV DNA in CD4+ T cells measured viral persistence.
FDG PET/CT uptake was higher among HIV-infected individuals
on ART and elite controllers compared to HIV-uninfected
individuals. Higher uptake of FDG was associated with higher
plasma HIV RNA load (r=0.556, P<0.001), despite correcting for
ART, CD4 count and history of opportunistic infections (P=0.006).
Additionally, higher LN FDG uptake was associated with viral
persistence among elite controllers (integrated HIV DNA in
peripheral blood mononuclear cells, r=0.85, P=0.015), but not in
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those whose HIV was suppressed on treatment. Finally, higher LN
FDG uptake was associated with higher markers of CD4+ T cell
activation in blood (HLADR+CD38+ cells: r=0.434, P=0.005) and
higher levels of plasma D-dimer (r=0.32, P=0.044).
These findings suggest that HIV production (and perhaps
replication) contributes to inflammation and/or a chronic
inflammatory environment in lymphoid tissues that may contribute
to persistence. FDG-PET/CT imaging of axillary LNs may provide
a method to non-invasively measure inflammation and assess
responses to different ART or anti-inflammatory interventions.
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BOOK REVIEW
ABC of domestic and sexual violence
Angelina Namiba*
Salamander Trust Associate
Bewley S and Welch J (Editors)
ABC of Domestic and Sexual Violence, 2014 is available from Wiley,
priced £21.99.
ISBN 978-1-118-48218-6
1 in 3 women worldwide have experienced physical or sexual
violence – mostly by an intimate partner [1]. It is one of the
most widespread abuses of human rights worldwide.
Aimed at healthcare professionals, this book is a very timely guide.
Particularly so because, due to the intimate nature of the
relationships they have with their patients, healthcare professionals
are in a unique position to identify the issue, empathise with their
patients and refer them for support. The book aims to provide
practical help to learners early in their careers. It starts with a
foreword by Sir George Alberti of the King‘s College NHS Trust
and also has a concise introduction by the editors.
Chapter authors are experts in the various fields of domestic and
sexual violence. They cover: the epidemiology of gender-based
violence; culture and violence; domestic violence and abuse; the
impact of trauma; children; sexual assault of men and boys;
identifying domestic violence and abuse; community-based
responses to domestic violence; sources of referral and support
for domestic violence; perpetrators; general practice; emergency
medicine and surgical procedures; elder abuse; the dental team;
mental health services; women‘s reproductive and sexual health
services; female genital mutilation; sexual violence; what to
consider; rape and sexual assault; medical and psychosocial care;
documenting in the notes; law and prosecuting practice in relation
to serious sexual assaults and domestic violence; writing a
statement as a professional witness; going to court; violation of
professional boundaries; and moving forward: developing care
pathways within the health service; and pursuing a career and
implementing better services.
Although it covers an extensive area, the style and layout of the
book make it easy for the reader to go directly to the relevant
topic or area of specialty. This is particularly so as the chapters
are short, clear, to the point and very practical. The use of
illustrations, question-and-response style and case studies, as well
as practical tips on assessment, examination, management and
referral of cases, make it a comprehensive and valuable guide.
The only small weakness of the book, from my perspective, is the
very basic coverage of HIV. There are sections covering testing
and post-exposure prophylaxis (PEP), and a small section covering
gender-based violence and links to HIV. Perhaps the authors could
consider including a chapter expanding on gender-based violence,
and the links to HIV, in a future edition.
All in all, this book is very well researched, expertly written and
engaging. In my opinion, it is the definitive guide. I would
recommend it highly to healthcare (and other) professionals in
the various fields, whether well established or just starting out
in their careers.
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